Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Marsillach, Judit ^a,b   Suzuki, Stephanie M ^a   Richter, Rebecca J ^a   McDonald, Matthew G ^b   Rademacher, Peter M ^b,c   MacCoss, Michael J ^b   Hsieh, Edward J ^b,d   Rettie, Allan E ^b   Furlong, Clement E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Department of Medicinal Chemistry University of Washington ^*  (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIPHENYL HYDROLASE LIKE PROTEIN; BLEOMYCIN HYDROLASE; ENZYME INHIBITOR; HOMOCYSTEINE THIOLACTONASE; HOMOCYSTEINE THIOLACTONE; IODOACETAMIDE; LIVER ENZYME; PROLINE BENZYL; RECOMBINANT BIPHENYL HYDROLASE LIKE PROTEIN; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VALACICLOVIR; ARYLDIALKYLPHOSPHATASE; BPHL PROTEIN, HUMAN; CARBOXYLESTERASE;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL CELL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PURIFICATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; HYDROLYSIS; MASS SPECTROMETRY; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; PH; PROTEIN EXPRESSION; ENZYMOLOGY; GENETICS; LIVER; METABOLISM;

ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; HUMANS; LIVER;

EID: 84908078103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110054     Document Type: Article

References (45)

1. Lentz SR (2005) Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3: 1646-1654.
2. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202.
3. Barathi S, Angayarkanni N, Pasupathi A, Natarajan SK, Pukraj R, et al. (2010) Homocysteinethiolactone and paraoxonase: novel markers of diabetic retinopathy. Diabetes Care 33: 2031-2037.
4. Yilmaz N (2012) Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci 8: 138-153.
5. Suszynska J, Tisonczyk J, Lee HG, Smith MA, Jakubowski H (2010) Reduced homocysteine-thiolactonase activity in Alzheimer's disease. J Alzheimers Dis 19: 1177-1183.
6. Seshadri S (2006) Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease. Journal of Alzheimer's Disease 9: 393-398.
7. Finkelstein JD (1998) The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 157 Suppl 2: S40-44.
8. Zimny J, Sikora M, Guranowski A, Jakubowski H (2006) Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J Biol Chem 281: 22485-22492.
9. Borowczyk K, Shih DM, Jakubowski H (2012) Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J Alzheimers Dis 30: 225-231.
10. Borowczyk K, Tisonczyk J, Jakubowski H (2012) Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase. Amino Acids 43: 1339-1348.
11. Jakubowski H (1999) Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 13: 2277-2283.
12. Jakubowski H (2000) Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 130: 377S-381S.
13. Jakubowski H (2002) The determination of homocysteine-thiolactone in biological samples. Anal Biochem 308: 112-119.
14. Joseph J, Handy DE, Loscalzo J (2009) Quo Vadis: Whither Homocysteine Research? Cardiovascular Toxicology 9: 53-63.
15. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, et al. (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335-1342.
16. Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957-3962.
17. Bayrak A, Bayrak T, Demirpence E, Kilinc K (2011) Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and R-192 PON1 isoenzymes. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 879: 49-55.
18. Costa LG, Cole TB, Jarvik GP, Furlong CE (2003) Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54: 371-392.
19. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, et al. (2000) Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10: 767-779.
20. La Du BN (2000) Historical Perspectives. In: Costa LG, Furlong, C.E., editor. Paraoxonase (PON1) in Health and Disease. Boston/Dordrecht/London: Kluwer Academic Publishers. pp.1-25.
21. Kosaka T, Yamaguchi M, Motomura T, Mizuno K (2005) Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 359: 156-162.
22. Jakubowski H (2010) The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 660: 113-127.
23. Bromme D, Rossi AB, Smeekens SP, Anderson DC, Payan DG (1996) Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 35: 6706-6714.
24. Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, et al. (1998) Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat Genet 18: 211-212.
25. Kajiya A, Kaji H, Isobe T, Takeda A (2006) Processing of amyloid beta-peptides by neutral cysteine protease bleomycin hydrolase. Protein Pept Lett 13: 119-123.
26. Puente XS, Lopez-Otin C (1995) Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds. J Biol Chem 270: 12926-12932.
27. Puente XS, Pendas AM, Lopez-otin C (1998) Structural characterization and chromosomal localization of the gene encoding human biphenyl hydrolaserelated protein (BPHL). Genomics 51: 459-462.
28. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, et al. (2003) Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 278: 25348-25356.
29. Kim I, Song X, Vig BS, Mittal S, Shin HC, et al. (2004) A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 1: 117-127.
30. Lai L, Xu Z, Zhou J, Lee KD, Amidon GL (2008) Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem 283: 9318-9327.
31. Long JZ, Cravatt BF (2011) The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chemical Reviews 111: 6022-6063.
32. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
33. Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, et al. (2003) Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal Biochem 312: 224-227.
34. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, et al. (2002) Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62: 162-172.
35. Korenovsky A, Laev H, Mukherjee S, Mahadik SP (1990) Quantitative analyses of plasma cholinesterase isozymes in haloperidol-treated rats. Biol Psychiatry 27: 871-883.
36. Eng JK, McCormack AL, Yates JR (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5: 976-989.
37. Burnette TC, Harrington JA, Reardon JE, Merrill BM, de Miranda P (1995) Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 270: 15827-15831.
38. McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128.
39. McCully KS (2005) Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 43: 980-986.
40. Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, et al. (2009) Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 119: 3384-3394.
41. Molina DK, DiMaio VJ (2012) Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol 33: 368-372.
42. Camps J, Joven J, Mackness B, Mackness M, Tawfik D, et al. (2011) Paraoxonase-1 and clopidogrel efficacy. Nat Med 17: 1041-1042; author reply 1042-1044.
43. Dansette PM, Rosi J, Debernardi J, Bertho G, Mansuy D (2012) Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring. Chem Res Toxicol 25: 1058-1065.
44. Koubaa N, Hammami S, Nakbi A, Ben Hamda K, Mahjoub S, et al. (2008) Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behcet's disease patients. Clin Chem Lab Med 46: 187-192.
45. Furlong CE (2008) Paraoxonases: An Historical Perspective. In: Paragh G, editor. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Dodrecht: Springer. pp. 3-31.